Stockscreener 앱 받기
6.145
2.08%
0.125
전일 마감가:
$6.02
열려 있는:
$6.02
하루 거래량:
132.82K
Relative Volume:
0.03
시가총액:
$587.77M
수익:
$829.00M
순이익/손실:
$-399.90M
주가수익비율:
-1.4238
EPS:
-4.3159
순현금흐름:
$-23.20M
1주 성능:
+10.92%
1개월 성능:
+47.36%
6개월 성능:
+27.23%
1년 성능:
-24.14%
1일 변동 폭
$5.97
$6.15
1주일 범위
$5.39
$6.07
52주 변동 폭
$2.74
$8.50
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.145 | 587.77M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
688.20 | 254.46B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
231.91 | 163.03B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
403.90 | 58.22B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
176.29 | 49.70B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.42 | 45.33B | 16.63B | 1.39B | 2.12B | 8.0674 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-20 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2026-09-09 | 재개 | UBS | Neutral |
| 2026-09-01 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-21 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Labcorp to spend $932 million on lab assets, acquire Millennium Health - Winston-Salem Journal
Labcorp to buy Myriad’s prenatal health testing unit for $210M - MedTech Dive
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers - The Manila Times
Myriad Genetics presents data on cancer recurrence detection test By Investing.com - Investing.com Canada
Myriad Genetics releases MRD cancer detection data at ESMO 2026 - StreetInsider
Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions - Yahoo Finance
After surgery, a test detected cancer DNA before each observed colorectal recurrence; median lead: 4 months. - Stock Titan
Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) - Seeking Alpha
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner - Yahoo Finance
Myriad Genetics to present at Wells Fargo healthcare conference - scanx.trade
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance Singapore
Stocks making big moves yesterday: Washington Trust Bancorp, Doximity, Myriad Genetics, Arhaus, and Gartner - FinancialContent
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Yahoo Finance
Form 8K Myriad Genetics Inc For: 20 October By Investing.com - Investing.com Nigeria
Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business - Investorideas.com
Why Is Myriad Genetics Stock Trading Higher Today?Myriad Genetics (NASDAQ:MYGN) - Benzinga
Current ratio of Myriad Genetics, Inc. – XETR:MYD - TradingView
Myriad Genetics stock surges on $210M prenatal unit sale - Yahoo Finance Singapore
Myriad Genetics stock surges on $210M prenatal unit sale - Investing.com
Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He - GuruFocus
Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday - Benzinga
Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210M - GenomeWeb
Myriad to sell prenatal health business to Labcorp (MYGN:NASDAQ) - Seeking Alpha
MYGN Stock Draws Bullish Targets As Prostate Cancer Push Builds - Timothy Sykes
MYGN Stock Draws Bullish Targets As Oncology Pivot Accelerates - StocksToTrade
Why is Myriad Genetics stock surging today? - Investing.com
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp - The Manila Times
Form 8K Myriad Genetics Inc For: 20 October By Investing.com - Investing.com India
Myriad Genetics to Sell Prenatal Health Division to LabCorp for $210 Million Cash - Kalkine Media
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp - Yahoo Finance
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know - Yahoo Finance
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
Myriad Genetics to report Q3FY26 results on November 4, 2026 - scanx.trade
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 - Yahoo Finance
What Myriad Genetics Doubters Saw Before The Drop - Yahoo Finance
SOPHiA GENETICS, Myriad Genetics and AstraZeneca Collaborate to Advance Precision Oncology in Prostate Cancer - BioPharma APAC
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology - PR Newswire
MYRIAD GENETICS INC MYRIAD GENE (0K3W.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Craig-Hallum raises target for Myriad Genetics stock from USD 4.00 to USD 8.00 - AD HOC NEWS
Craig-Hallum raises target for Myriad Genetics stock from USD 4.00 to USD 8.00 - AD HOC NEWS
Myriad Genetics, Inc. (0K3W.L) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets - Yahoo Finance
Myriad Genetics (Nasdaq:MYGN)Stock Analysis - Simply Wall Street
Why Is Myriad Genetics (MYGN) Stock Soaring Today - FinancialContent
Why Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
Form 4 Myriad Genetics Inc For: 27 September By Investing.com - Investing.com South Africa
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Myriad Genetics (MYGN) ex-CCO keeps stock-tied PSUs - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Challenges in Diagnostics & Research - DirectorsTalk Interviews
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Myriad Genetics Inc 주식 (MYGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kumar Rashmi | Director |
Jun 08 '26 |
Proposed Sale |
4.59 |
15,000 |
68,850 |
0 |
| Bisaro Paul | Director |
May 14 '26 |
Buy |
3.69 |
7,500 |
27,638 |
97,441 |
| Raha Samraat S. | President and CEO |
Mar 09 '26 |
Buy |
5.00 |
40,000 |
199,844 |
493,104 |
| Phanstiel S. Louise | Director |
Feb 27 '26 |
Buy |
4.66 |
48,000 |
223,728 |
281,951 |
| Phanstiel S. Louise | Director |
Feb 26 '26 |
Buy |
4.80 |
50,407 |
242,105 |
233,951 |
| Phanstiel S. Louise | Director |
Feb 25 '26 |
Buy |
4.74 |
6,100 |
28,890 |
183,544 |
0.49%
0.95%
자본화:
|
볼륨(24시간):